Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
BUSINESS ACCOUNT
Sign up for a business account to:
-
Access reports individually or via Subscription
-
Receive monthly invoices with payment via CSA or hard dollars
Get access to other exclusive features
-
Analyst access
-
Free Trial Subscriptions
-
Team account with shared subscriptions
-
Advanced analytics to track research consumption and performance
Oscar Haffen Lamm
- Oscar Haffen Lamm
Egetis: Multiple abstracts published ahead of the ETA
Ahead of the ETA conference Egetis published seven abstracts related to MCT8 deficiency and tiratricol. While two of the abstracts were already published, of which the tiratricol's benefit on mortality (note here), these new findings will further support the understanding of MCT8 deficiency and esp
Aurelien Deside
- Aurelien Deside
Planisware: Ardian to sell its remaining shares
In line with our fears highlighted yesterday, Ardian, the PE fund that entered the capital in 2003 and sold the majority of its shares during the IPO in April, plans to sell its remaining 4.6% stake in Planisware, at a price of EUR25.75 (source Bloomberg), capitalising on the company's share price
Maria Vara
- Maria Vara
Median Technologies: eyonis LCS webinar insights
Yesterday, Median hosted a Webinar to dive into eyonis REALITY pivotal study results in Lung Cancer Screening (LCS), which came out a week ago (here), setting clear ground on its outstanding performance on a patient-level detection with an AUC of 0.903, significantly above the 0.8 threshold predefi
Oscar Haffen Lamm
- Oscar Haffen Lamm
MedinCell: 99% done... 1% to go!
Teva provided an update on the phase 3 trial of mdc-TJK (LAI olanzapine), with 99% of the targeted injections (necessary for submission) no PDSS events have been observed. Combined with the positive efficacy results presented in May 2024, should the safety data on PDSS read out favourably, mdc-TJK
Aurelien Deside
- Aurelien Deside
Planisware Initiation: high-quality Rule of 50
We initiate coverage of Planisware with a Neutral rating (link here), recommending that investors place this high-quality and high-growth cash machine on their watchlist and wait for a more attractive entry price that would provide an adequate margin of safety, upside and compensation for very inte
Gregory Ramirez
- Gregory Ramirez
Thibault Morel
- Thibault Morel
Cedric Rossi
- Cedric Rossi
HUGO BOSS: Successful execution and healthy geo mix lead to raised FY2...
HUGO BOSS - NEUTRAL | EUR68 vs. EUR64 Successful execution and healthy geo mix lead to raised FY22 guidance Strong sales and EBIT beat in Q2 driven by execution… … and low exposure to China’s lockdowns FY22 sales and EBIT guidance revised upwards and we increase our FY22-23 estimates by 7%
Clement Genelot
- Clement Genelot